Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1997-08-13
1999-11-02
Housel, James C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 71, 435 74, 435 792, 435 793, 435 794, 435 795, 436811, 530380, G01N 3353, G01N 33573, A61K 3514
Patent
active
059768096
DESCRIPTION:
BRIEF SUMMARY
The present invention provides an immunoassay for the measurement of trypsinogen-2 either as free trypsinogen-2 in urine or as its complex with alpha-1-antitrypsin (trypsin-2-AAT) in serum. The invention relates further to a method for differentiating between pancreatitis and other pancreatic disease on one hand and non-pancreatic gastrointestinal disease on the other hand by determining either free trypsinogen-2 in urine or trypsin -2-AAT in serum.
BACKGROUND OF THE INVENTION
The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
The trypsinogens are serine proteases secreted by exocrine cells of the pancreas (Travis J and Roberts R. Biochemistry 1969; 8: 2884-9; Mallory P and Travis J, Biochemistry 1973; 12: 2847-51). Two major types of trypsinogen isoenzymes have been characterized, trypsinogen-1, also called cationic trypsinogen, and trypsinogen-2 or anionic trypsinogen. The trypsinogen proenzymes are activated to trypsins in the intestine by enterokinase, which removes an activation peptide from the N-terminus of the trypsinogens. The trypsinogens show a high degree of sequence homology, but they can be separated on the basis of charge differences by using electrophoresis or ion exchange chromatography. The major form of trypsinogen in the pancreas and pancreatic juice is trypsinogen-1 (Guy CO et al., Biochem Biophys Res Commun 1984; 125: 516-23). In serum of healthy subjects, trypsinogen-1 is also the major form, whereas in patients with pancreatitis, trypsinogen-2 is more strongly elevated (Itkonen et al., J Lab Clin Med 1990; 115:712-8). Trypsinogens also occur in certain ovarian tumors, in which trypsinogen-2 is the major form (Koivunen et al., Cancer Res 1990; 50: 2375-8). Trypsin-1 in complex with alpha-1-antitrypsin, also called alpha-1-antiprotease, has been found to occur in serum of patients with pancreatitis (Borgstrom A and Ohlsson K, Scand J Clin Lab Invest 1984; 44: 381-6) but determination of this complex has not been found useful for differentiation between pancreatic and other gastrointestinal diseases (Borgstrom et al., Scand J Clin Lab Invest 1989; 49:757-62).
Trypsinogen-1 and -2 are closely related immunologically (Kimland et al., Clin Chim Acta 1989; 184: 31-46; Itkonen et al., 1990), but by using monoclonal antibodies (Itkonen et al., 1990) or by absorbing polyclonal antisera (Kimland et al., 1989) it is possible to obtain reagents enabling specific measurement of each form of trypsinogen.
When active trypsin reaches the blood stream, it is inactivated by the major trypsin inhibitors alpha-2-macroglobulin and alpha-1-antitrypsin (AAT). AAT is a 58 kilodalton serine protease inhibitor synthesized in the liver and is one of the main protease inhibitors in blood. Whereas complexes between trypsin-1 and AAT are detectable in serum (Borgstrom and Ohlsson, 1984) the complexes with alpha -2-macroglobulin are not measurable with antibody-based assays (Ohlsson K, Acta Gastroenterol Belg 1988; 51: 3-12).
Acute pancreatitis is a severe and potentially lethal disease requiring rapid diagnosis. Determinations of amylase in serum or urine are routinely used for this purpose, but these methods are hampered by lack of specificity, which limits their clinical usefulness. Therefore, the use of other pancreatic markers, e.g. proteases and lipases have gained interest (Ogawa et al., Nippon Geka Gakkai Zassshi 1985; 86: 1241-4). Determination of trypsinogen-1 and -2 in serum (Itkonen et al., 1990) and trypsinogen-1 in urine (Lake-Bakaar et al., Lancet 1979; ii: 878-80) have been used for diagnosis of pancreatic disease.
In the present invention it has been shown that patients with pancreatic disease have strongly elevated concentrations of trypsinogen-2 complexed with alpha-1antitrypsin in serum and free trypsinogen-2 in urine. Accordingly, this discovery has proved to be very useful in the diagnosis of pancreatitis.
BRIEF DESCRIPTION OF THE DRA
REFERENCES:
Vercaigne-Marko, D. (1989). "Human Cationic and Anionic Trypsins: Differences of Interaction with .alpha..sub.1 -Proteinase Inhibitor." Biol. Chem. Hoppe-Seyler 370:1163-1171.
Itkonen, O. et al. (1990). "Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis." J. Lab Clin. Med. 115:712-718.
Koivunen, E. et al. (1990). "Cyst Fluid of Ovarian Cancer Patients Contains High Concentrations of trypsinogen-2." Cancer Res. 50:2375-2378.
Chem. Abstracts 114:243198x (1991).
Chem. Abstracts 115:3672z (1991).
Dialog Information Service, file 155, Medline, Dailog accession No. 05400454, Medline accession No. 85016454 Abstract of Borgstrom A. et al., Scand. J. Clin. Lab. Invest. 44:381-6 (1984). 1985 accession No.
Dialog Information Service, file 155, Medline, Dialog accession No. 06301754, Medline accession No. 87275754 Abstract of Fabris, C. et al., Enzyme 37:174-81 (1987).
National Library of Medicine, file Medline, Medline accession No. 94349572 Abstract of Hedstr:om, J. et al., Clin. Chem. 40:1761-5 (1994).
Guy et al., "Two Human Trypsinogens, Purification, Molecular Properties, and N-Terminal Sequences," Biochemistry, 17(9):1669-1675, 1978.
Hedstrom et al., "Time-Resolved Immunofluorometric Assay of Trypsin-2 Complexed with alpha-1-Antitrypsin in Serum," Clinical Chemistry, 40(9):1761-1765, Sep. 1994.
Hedstrom et al., "Urine trypsinogen-2 as marker of acute pancreatitis," Clinical Chemistry, 42(5):685-690, 1996.
Hedstrom et al., "Urinary trypsinogen-2 test strip for acute pancreatitis," The Lancet, 347:729-731, Mar. 16, 1996.
Kemppainen et al., "Rapid Measurement of Urinary Trypsinogen-2 as a Screening Test for Acute Pancreatitis," The New England Journal of Medicine, 336(25):1788-1793, Jun. 19, 1997.
Kimland et al., "Immunoreactive anionic and cationic trypsin in human serum," Clinica Chimica Acta, 184:31-46, 1989.
Hedstrom Johan
Stenman Ulf-H.ang.kan
Hines Ja-Na A.
Housel James C.
Stenman Ulf-Hakan
LandOfFree
Assay of free and complexed trypsinogen-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay of free and complexed trypsinogen-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay of free and complexed trypsinogen-2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2133306